Shimadzu Europe
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • FREE newsletter subscription
  • Search
  • Menu Menu
Clinical Laboratory int.
  • Allergies
  • Cardiac
  • Gastrointestinal
  • Hematology
  • Microbiology
  • Microscopy & Imaging
  • Molecular Diagnostics
  • Pathology & Histology
  • Protein Analysis
  • Rapid Tests
  • Therapeutic Drug Monitoring
  • Tumour Markers
  • Urine Analysis

Archive for category: E-News

E-News

shutterstock 633855362

Antibiotics administered to mothers during childbirth linked to autoimmune diseases in children

, 18 March 2024/in E-News /by panglobal

Children whose mothers have received antibiotic treatment during childbirth are more likely to develop autoimmune diseases compared to their counterparts, according to a recent registry-based study conducted at the University of Oulu, Finland, involving nearly 46,000 children. The most common autoimmune diseases in children include type 1 diabetes, celiac disease, and rheumatic diseases. However, the […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2024/03/shutterstock_633855362.jpg 1280 1920 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2024-03-18 09:26:032024-03-18 09:26:03Antibiotics administered to mothers during childbirth linked to autoimmune diseases in children
checkpoint

New checkpoint identified to fight solid tumours

, 15 March 2024/in E-News /by panglobal

A study by a scientific team from the University of Vienna and the MedUni Vienna, published in Cellular & Molecular Immunology [1], has a promising result from tumour research: The enzyme phosphoglycerate dehydrogenase (PHDGH) acts as a metabolic checkpoint in the function of tumour-associated macrophages (TAMs) and thus on tumour growth. Targeting PHGDH to modulate […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2024/03/checkpoint.jpg 1202 1202 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2024-03-15 08:06:142024-03-15 08:06:14New checkpoint identified to fight solid tumours
shutterstock 1921460882

Detailed study demonstrates how pulse oximeters significantly overestimate oxygen readings in people with darker skin tones

, 15 March 2024/in E-News /by panglobal

Pulse oximeters – one of the most common medical devices used in global healthcare – can provide significantly overestimated oxygen saturation readings in people with darker skin tones, according to the most comprehensive study ever to explore the issue.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2024/03/shutterstock_1921460882.jpg 1280 1920 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2024-03-15 08:01:332024-03-15 08:01:33Detailed study demonstrates how pulse oximeters significantly overestimate oxygen readings in people with darker skin tones
head brains

Study findings turn gut-brain communication on its axis

, 14 March 2024/in E-News /by panglobal

The mechanisms by which antidepressants and other emotion-focused medications work could be reconsidered due to an important new breakthrough in the understanding of how the gut communicates with the brain.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2024/03/head-brains.jpg 1920 1920 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2024-03-14 13:43:062024-03-14 13:43:06Study findings turn gut-brain communication on its axis
Robert Quinn

Research collaboration make breakthrough in bile acid study

, 14 March 2024/in E-News /by panglobal

Ask someone what they think of when they hear the phrase “bile acids”, and you might get a few unpleasant answers.  

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2024/03/Robert-Quinn.jpg 1508 1312 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2024-03-14 13:37:442024-03-14 13:37:44Research collaboration make breakthrough in bile acid study
liver fibrosis

VUB research team discovers essential protein that contributes to liver fibrosis

, 14 March 2024/in E-News /by panglobal

Chronic liver disease is a serious global health problem that has a severe impact on personal quality of life. A major characteristic of chronic liver disease is liver fibrosis, where certain liver cells, called hepatic stellate cells, become activated and produce scar tissue that damages the liver. At present, no specific drugs are available to […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2024/03/liver_fibrosis.jpg 1441 1920 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2024-03-14 13:30:482024-03-14 13:30:48VUB research team discovers essential protein that contributes to liver fibrosis
lobelia samavati

Scientists develop simple blood test to quickly diagnose sarcoidosis

, 14 March 2024/in E-News /by panglobal

A research project led by Lobelia Samavati, M.D., professor of internal medicine and molecular medicine and genetics at the Wayne State University School of Medicine, and supported by the National Institutes of Health (NIH), has developed a tool to rapidly and inexpensively diagnose sarcoidosis, a chronic inflammatory disease marked by the growth of tiny lumps […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2024/03/lobelia_samavati.jpg 848 678 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2024-03-14 13:28:122024-03-14 13:28:12Scientists develop simple blood test to quickly diagnose sarcoidosis
shutterstock 1948617478

Novartis to acquire Calypso Biotech and CALY-002 therapeutic antibody

, 14 March 2024/in E-News /by panglobal

Novartis will acquire Calypso Biotech, a developer of Interleukin15 (IL-15) targeted therapies, for US$250 million plus a further $175 million based on the achievement of certain predetermined milestones.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2024/03/shutterstock_1948617478.jpg 787 1920 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2024-03-14 11:50:532024-03-14 13:24:55Novartis to acquire Calypso Biotech and CALY-002 therapeutic antibody
shutterstock 1819138538

Gilead Sciences set to acquire CymaBay Therapeutics for $4.3bn

, 14 March 2024/in E-News /by panglobal

Gilead Sciences will acquire CymaBay Therapeutics for US$4.3 billion. The acquisition will see Gilead add CymaBay’s investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis (PBC) including pruritus, to their existing liver therapy portfolio.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2024/03/shutterstock_1819138538.jpg 956 1920 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2024-03-14 11:47:332024-08-21 13:41:33Gilead Sciences set to acquire CymaBay Therapeutics for $4.3bn
Scherm­afbeelding 2024 03 14 om 12.39.39

PrecisionLife and Metrodora Institute partner to accelerate diagnosis, treatment of Long COVID, ME/CFS

, 14 March 2024/in E-News /by panglobal

PrecisionLife, and leading US multi-specialty healthcare center, and Metrodora Institute, are co-investing in a first-of-its-kind partnership to jumpstart the diagnosis and treatment options for a range of complex, chronic diseases including Long COVID, ME/CFS, ALS, Sjögren’s syndrome, and many more. The partners will first develop and validate genotypic diagnostics that provide clinicians with an accurate […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2024/03/Scherm­afbeelding-2024-03-14-om-12.39.39.jpg 534 1644 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2024-03-14 11:40:242024-03-14 11:40:24PrecisionLife and Metrodora Institute partner to accelerate diagnosis, treatment of Long COVID, ME/CFS
Page 25 of 228«‹2324252627›»
Bio-Rad - Preparing for a Stress-free QC Audit

Latest issue of Clinical laboratory

November 2025

CLi Cover nov 2025
15 December 2025

WERFEN APPLAUDS SIGNIFICANT PUBLICATION URGING ACTION ON THE RISKS OF UNDETECTED HEMOLYSIS

13 December 2025

Indero validates three-day gene expression method

12 December 2025

Johnson & Johnson acquires Halda Therapeutics for $3.05 billion

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The leading international magazine for Clinical laboratory Equipment for everyone in the Vitro diagnostics

Sign up today
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release
clinlab logo blackbg 1

Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com

PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only

Subscribe now!

Become a reader.

Free subscription